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Abstract. Amaryllidaceae plants are known for their ornamental 
flowers all over the word, but they also have a medicinal value 
owing to their exclusive group of alkaloids. The Amaryllidaceae 
alkaloids have a wide range of important biological activities, 
notably anti-tumoral, anti-parasitic, and acetylcholinesterase 
inhibition. This review focuses on the chemical characteristics of 
Amaryllidaceae plants and alkaloids, as well as the different 
methodologies applied in their study, including promising new 
docking studies.   
     
Introduction 
  
 Amaryllidaceae plants are known for their outstanding attractive flowers 
(Figure 1), and are widely used and cultivated for ornamental purposes.                  
For example, Narcissus species are extensively cultivated and exported for 
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ornamental use in the UK and the Netherlands, as are Lycoris species in 
China and Japan, while Crinum species are appreciated for their lily-like 
flowers [1]. 
 
 
 
Figure 1. Hymenocallis spp. (Amaryllidaceae) from Venezuela 
 
 Amaryllidaceae plants also have a long history of use for medicinal 
purposes. The specific type of alkaloids they contain, named Amaryllidaceae 
alkaloids, display a wide range of biological activities such as antiviral, 
antimalarial, anticancer and anticholinesterasic [2]. 
 
1. Amaryllidaceae family characteristics 
 
 The Amaryllidaceae family, of the order Asparagales, consists of 
bulbous flowering plants, and is divided in three subfamilies 
(Agapanthoideae, Allioideae and Amaryllidoideae) previously considered 
as three separate families. The term “Amaryllidaceae”, whether referring to 
plants or alkaloids, is ubiquitous in the phytochemical and pharmaceutical 
literature on the subfamily Amaryllidoideae [1, 3]. The monocotyledonous 
Amaryllidoideae subfamily comprises around 1000 species in 60 genera 
with a pantropical distribution, above all in three geographic locations: 
Andean South America, Southern Africa and the Mediterranean coast.  
Amaryllidoideae plants have a high capacity for adaptation. Those of the 
genera Leptochiton and Paramongaia survive in areas with a very arid 
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climate, since bulbs can remain latent for long periods, while Hippeastrum 
and Hymenocallis thrive in humid woods [4]. 
 The medicinal use of Amaryllidaceae plants goes back to the Classical 
period, when Hippocrates and Dioscorides were already using Narcissus 
oil to treat illnesses thought to be linked to uterine tumours. References to 
Narcissus usage against cancer are also found in Pliny the Elder and the 
Bible. Today Amaryllidaceae plants are still extensively used in traditional 
medicine in several countries. For example, Ammocharis is cooked and 
used as an enema for blood cleansing or to cure open wounds; bulbs of 
Brunsvigia are applied as antiseptic dressing on fresh wounds and their 
decoctions treat coughs, colds, and liver diseases; Clivia species are used 
to treat snakebites and wounds, and to facilitate birth; Crinum species are 
applied as a powerful emetic, to treat tumours (Asia and America) and 
colds, wash wounds and haemorrhoids, as a gynecological remedy (South 
Africa) and a rubefacient in the treatment of rheumatism (India) [5]. 
 
2. Amaryllidaceae alkaloids 
 
 Virtually exclusive to the Amaryllidoideae subfamily, the Amaryllidaceae 
alkaloids have anti-viral, anti-parasitic, anti-cancer and anti- cholinesterasic 
 
 
 
Figure 2. Three options of cyclization of the precursor O-methylnorbelladine and the 
resulting alkaloid types. 
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activities, which are probably the origin of many of the traditional medicinal 
uses of Amaryllidaceae plants. Although structurally diverse, 
Amaryllidaceae alkaloids are biogenetically related and can be classified into 
nine basic skeleton groups: norbelladine-, lycorine-, homolycorine-, crinine-, 
haemanthamine-, narciclasine-, tazettine-, montanine-, and galanthamine-
types. However, there are exceptions like graciline or plicamine, which 
cannot be classified in any of these classical groups, and a new plicamine-
type alkaloid was recently identified in Narcissus broussonetii [6]. 
 All Amaryllidaceae alkaloids derive from the amino acids                               
L-phenylalanine and L-tyrosine, from which the common precursor                                  
O-methylnorbellamine is synthesized. A final cyclisation step with different 
phenol oxidative couplings leads to a diversification of structures (Figure 2) 
[7]. 
 
3. Study of the genus Narcissus 
  
 The genus Narcissus comprises more than one hundred wild species and 
is mainly distributed around the Mediterranean Sea, including south-
western Europe, North Africa, Italy and the Balkans. This genus has an 
ornamental value, and its easy hybridization has allowed numerous 
cultivars to be developed. 
 The traditional medicinal uses of this genus are well documented. The 
Bible mentions the treatment of symptoms that could now be defined as 
cancer with Narcissus poeticus. Chinese, North African and Arabian 
medicine continues using this treatment. Today, it is known that                           
N. poeticus contains 0.012% of the anteneoplasic agent narciclasine [8].  
 The first isolated Amaryllidaceae alkaloid was lycorine, from 
Narcissus pseudonarcissus by Gerrard in 1877 [9]. Since then, numerous 
Amaryllidaceae alkaloids have been isolated in more than 40 wild species 
and over 100 cultivars. The most common alkaloids in Narcissus species 
are lycorine- and homolycorine-types; notably, they do not contain crinine-
type alkaloids, as they synthesise alkaloids with the 5,10b-ethano bridge in 
an α, not β position [8]. 
 Amaryllidaceae alkaloids isolated in the genus Narcissus were reviewed 
by Bastida et al. (2006) [8], and others have been identified by the same 
group since then [6, 7, 10, 11, 12, 13, 14].  
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4. Amaryllidaceae plants in traditional medicine in South Africa  
 
 Folk medicine still plays a crucial role in the healthcare of a great part of 
the population in South Africa. It has been estimated that around 27 million 
South Africans consult traditional healers. Contrary to popular belief, this 
practice is not restricted to poor and uneducated people, whose access to 
western medicine is limited by cost or distance, but extends to all sectors of 
the society [15, 16]. 
 The use of Amaryllidaceae plants in traditional South African 
medicine by indigenous people has a long history, and some applications 
were also adopted by early European colonists. Today several concoctions, 
decoctions, extracts and herbal preparations of Amaryllidaceae species can 
be found in local traditional medicinal markets. For example, Apodolirion 
buchananii is taken for stomach disorders and Brunsvigia species are used 
against infertility in [16]. Since the application of Amaryllidaceae plants to 
wounds is widespread, it was suspected that they had antibacterial 
properties. Indeed, several Amaryllidaceae alkaloids have been isolated 
and identified in these plants and their antibacterial [17], antifungal [18] 
antiviral [19], anti-inflammatorial and antiparasitic [18] activities have 
been determined. 
 
5. Amaryllidaceae alkaloids from Amaryllidaceae plants in        
Ibero-America 
 
 Ibero-America, together with South Africa, is a centre of 
diversification of the Amarylloideae subfamily. While many species 
remain unexplored, knowledge of Ibero-American Amaryllidaceae plants 
has advanced considerably in recent years. For example, the novel alkaloid 
phaedranamine was identified together with 7 known alkaloids in 
Phaedranassa dubia (Colombia) [20]. Zephyranthes concolor (Mexico) 
was studied for the first time in 2011 and 6 Amaryllidaceae alkaloids were 
identified [21]. Wild Amaryllidaceae species (Habranthus jamesonii, 
Phycella herbertiana, Rhodophiala mendocina, and Zephyranthes filifolia) 
from the Argentinian Andes were analysed for their alkaloid composition 
for the first time in 2011, revealing the presence of galanthamine and good 
acetylcholinesterase activity [22]. The alkaloid composition of the 
Colombian endemic species Caliphruria subedentata, one of only four 
species of the infrequent genus Caliphruria, was analysed by GC-MS and 
18 alkaloids were identified, in addition to six others isolated with classical 
phytochemical methods [23]. The new alkaloid 1-epidemethylbowdensine 
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was reported for the first time in Crinum erubescens collected in Costa 
Rica [24].  
 Hippeastrum is a well-known ornamental genus from South America 
with around 70 species, 34 of them found in Brazil, which according to 
nrDNA ITS sequences is the area of origin of the genus [25]. In a review 
focusing on the chemistry and biological activity of Amaryllidaceae 
alkaloids in the genus Hippeastrum, de Andrade et al. (2012) [25] include 
several new Amaryllidaceae alkaloids they identified for the first time, 
notably 2α,7-dimethoxyhomolycorine and candimine in Hippeastrum 
morelianum [26], and 11β-hydroxygalanthamine in Hippeastrum papilio 
[27]. Other new alkaloids have been identified for the first time in the 
Brazilian species Hippeastrum aulicum and H. calyptratum (aulicine,           
3-O-methylepimacowine, 11-oxohaemanthamine and 7-methoxy-O-
methyllycorenine) [28], and H. breviflorum (9-O-demethyllycosinine B) 
[29]. Recently, more new Amaryllidaceae alkaloids have been identified in 
H. papilio (hippapiline, papiline, 3-O-demethyl-3-O-(3-hydroxybutanoyl)-
haemanthamine) [30].  
 In Argentina, the genus Hippeastrum comprises nine widely 
distributed and poorly studied species, some of them used in traditional 
medicine by the Toba indigenous community. H. argentinum has recently 
been studied in terms of alkaloid composition and biological activity and 
two new alkaloids were identified (4-O-methylnangustine and                       
7-hydroxyclivonine). Furthermore, promising docking studies activities are 
being carried out [31].  
 
6. Study of galanthamine-producing species 
 
 Galanthamine is an Amaryllidaceae alkaloid sold as a drug under the 
commercial name of Reminyl
®
 in Europe and Razadine
®
 in the USA for 
the palliative treatment of mild to moderate stages of Alzheimer‟s 
disease. Galanthamine can be obtained by chemical synthesis, but the 
yield is too low to be economically feasible. Instead, it is obtained from 
natural sources such as Galanthus nivalis, Leucojum aestivum, Lycoris 
radiata and different species of Narcissus. However, several problems, 
including unsuccessful cultivation or slow regeneration, make it difficult 
to meet the increasing pharmaceutical demands for this drug [14]. 
Another issue is the great chemodiversity in one of the main industrial 
sources of galanthamine, Leucojum aestivum. Balearic populations of 
this species have an alkaloid profile dominated by crinine-type 
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compounds, while in those close to the Danube River homolycorine-type 
alkaloids are dominant. In populations from east Bulgaria the main 
alkaloid is lycorine, and only populations in south Bulgaria were found 
to predominantly contain galathamine-type compounds. Thus, the content 
of galanthamine in Leucojum aestivum can range from 0.2 to 95% of 
total alkaloids [32]. 
 More than 27,000 names of Narcissus ornamental cultivars have been 
registered in the International Daffodil Register and some intersectional 
cultivars have also been reported as potential sources of galanthamine. These 
cultivars present some advantages for alkaloid production, as they are less 
affected by planting depth and density, and large-scale cultivation has already 
been established for the ornamental plant industry [14]. In this                         
context, 105 ornamental varieties of Narcissus were analysed by GC-MS for 
 
 
 
Figure 3. Narcissus varieties with highest galanthamine content 
Laura Torras-Claveria et al. 76 
their galanthamine content and acetylcholinesterase inhibitory activity, 
distinguishing between bulbs and leaf tissues. The highest content of 
galanthamine was found in leaves from N. hispanicus, followed by the 
cultivars „Rijnveld Early Sensation‟ and „Rip van Winkle‟, and the bulbs 
of the cultivars „Yellow Wings‟ and „Bella Estrella‟, which could 
constitute promising new sources of this valuable metabolite (Figure 3) 
[14]. 
 The total alkaloid composition of these varieties was also determined by 
GC-MS, comparing alkaloid mass spectra and the Kovats Retention Index 
with those of authentic standards previously isolated and identified by 
spectroscopic methods by our group in other Amaryllidaceae plants. Also, a 
k-means cluster analysis was performed with ornamental varieties according 
to the alkaloid composition of leaves and bulbs separately, obtaining 5 
clusters of cultivars in each tissue. A correspondence analysis was performed 
to detect a possible relationship between those clusters according to the 
alkaloid composition and horticultural divisions of Narcissus ornamental 
varieties [7]. 
 
7. Pharmacological activity 
 
7.1. Antitumoral 
 
 Antitumoral activity was one of the first biological effects attributed to 
Amaryllidaceae plants. In the early 1980s, several reports on cytotoxic and 
antineoplastic activities of certain Amaryllidaceae alkaloids appeared, but 
it was in 1995 when a significant number of Amaryllidaceae alkaloids with 
different skeleton types were evaluated for their cytotoxicity against a 
panel of human and murine cell lines. While almost all Amaryllidaceae 
alkaloids tested were active against fibroblastic LMTK murine cells, 
pretazettine was the most active against human tumoral Molt4 lymphoid 
cells, but with no activity against human tumoral hepatoma cells, HepG2. 
Conversely, lycorenine was the most active against HepG2 cells, and 
almost inactive against Molt4 cells [33]. Since then, other Amaryllidaceae 
alkaloids have proved active against other cell lines [34, 35, 36]. Selective 
apoptosis-inducing effects have been observed in Amaryllidaceae alkaloids 
of different structural types, leading to structure-activity studies (SAR). 
For example, an α-ethanobridge and a free hydroxyl at the C-11 position 
are required for the potent apoptosis induced by crinane- and lycorine-type 
Amaryllidaceae alkaloids in tumor cells [37, 38, 39]. The 
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phenanthridinones, exemplified by narciclasine and pancratistatine, have 
recently attracted considerable interest owing to their potent cell                  
line-specific anticancer activities and minimal effect on normal cells, and a 
clinical candidate is earmarked for commercialisation in the next decade. 
Their mechanism is thought to be based on the initiation of cell death via 
the apoptotic pathway [40]. 
 
7.2. Antiparasitic 
 
 Antiparasitic properties have been found in some Amaryllidaceae 
alkaloids. For example, lycorine, augustine and crinamine are the principal 
antimalarial constituents of Crinum amabile, especially augustine, which 
inhibited both chloroquine-sensitive and chloroquine-resistant strains of 
Plasmodium falciparum. Haemanthamine, haemanthidine,                                           
3-epihydroxybulbispermine, galanthine and pancracine are also particularly 
active against these parasites, some even more so than the standards 
currently used for treatment [41]. 
 In relation to Chagas disease and Sleeping Sickness, haemanthidine, 
pancracine, 3-O-acetylsanguinine and 1,2-O-diacetyllycorine showed 
biological activity against Trypanosoma cruzi and Trypanosoma                  
brucei-rhodesiense [20]. The activity of alkaloids isolated in Phaedranassa 
dubia was evaluated against a range of parasitic protozoa, and ungeremine 
showed the best activity against T. brucei-rhodesiense, T. cruzi and                      
P. falciparum [20]. Compounds from Galanthus trojanus also demonstrated 
antiparasitic properties, protopine being especially promising for its high 
selectivity and potency against T. brucei-rhodesiense and P. falciparum K1, 
which is a drug-resistant strain [42]. Also, the ethanolic extract of                    
Narcissus broussonetii demonstrated significant activity against T. cruzi [6].  
 
7.3. Acetylcholinesterase inhibition 
 
 Inhibition of the acetylcholinesterase enzyme is one of the most 
important biological activities of certain Amaryllidaceae alkaloids. 
Galanthamine is currently the only Amaryllidaceae alkaloid commercially 
sold for the treatment of mild-to-moderate stages of Alzheimer‟s disease, 
owing to its capacity to inhibit the enzyme acetylcholinesterase in the brain 
and, at same time, interact with nicotinic receptors. Thus, the levels of 
acetylcholine in the brain, which decline in people with Alzheimer‟s disease, 
can be maintained [1, 43]. Inhibition of acetylcholinesterase activity has 
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been reported in other Amaryllidaceae alkaloids, including sanguinine, 
montanine, 11-hydroxygalanthamine, epinorgalanthamine, and assoanine 
[44, 45, 46], and some of them, such as sanguinine, are even more potent 
than galanthamine. However, the extra hydroxyl group of sanguinine, 
available for the interaction with acetylcholinesterase, makes the molecule 
more hydrophilic, thus reducing its ability to cross the blood-brain barrier 
[47]. Also, natural N-alkylated galanthamine derivatives such as                          
N-allylnorgalanthamine and N-(14-methylallyl)norgalanthamine demonstrate 
a higher inhibition of acetylcholinesterase than galanthamine [48]. 
  
7.4. Docking studies 
 
 Docking is the use of computational methods to predict the preferred 
conformation of one molecule to another when they form a stable complex 
[49]. Docking studies performed with several Amaryllidaceae alkaloids 
and acetylcholinesterase and butyrylcholinesterase enzymes have revealed, 
for example, that not only galanthamine-type alkaloids could be useful for 
the treatment of Alzheimer‟s disease. Tazettine-type alkaloids should also 
be considered owing to the high selectivity of 3-epimacronine derivatives 
for binding the enzyme locus [50]. Docking and molecular dynamics 
simulation studies have recently shown butyrylcholinesterase inhibitory 
 
 
 
Figure 4. Putative binding mode of narciclasine in GSK-3β enzyme. 
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activity in 7- hydroxyclivonine, which interacts at the same binding site of 
the enzyme as galanthamine with very similar amino acids (Ortiz et al.,  
2016). Perspectives for the future include research into glycogen synthase 
kinase 3  (GSK3 ) as a new therapeutic target for Amaryllidaceae 
alkaloids. This enzyme is involved in several cellular processes, including 
some proteins involved in Alzheimer‟s disease. Furthermore, there is a 
growing interest in GSK3  from unicellular parasites, due to their 
prominent role in the regulation of circadian rhythms of parasites, which 
are responsible, for example, for the circadian fever caused by                       
P. falciparum, (Figure 4) [51]. 
 
8. Conclusion 
 
 Amaryllidaceae plants are outstanding, economically important plants, 
not only for their ornamental value, but also as medicinal plants and 
sources of drugs and new therapeutic targets. Due to their considerable 
biodiversification, they are found in almost all the continents: Europe, 
Asia, Africa and America. Their use in traditional medicine remains 
important in certain areas, and is supported by numerous scientific studies 
that have demonstrated the bioactivity of these plants, caused by their 
content of a particular and exclusive type of alkaloids, named 
Amaryllidaceae alkaloids. 
 
Acknowledgements 
 
 The authors, members of the group 2014 SGR920, are grateful to               
Dr. A. Marín, Dr. M. A. Molins, Dr. A. Linares, Dr. M. Feliz and                
Dr. O. Jáuregui from the Scientific and Technological Services of the 
University of Barcelona. 
 
References 
 
1. Takos, A. M., Rook, F. 2013, Int. J. Mol. Sci., 14, 11713. 
2. Bastida, J., Berkov, S., Torras-Claveria, L., Pigni, N. B., de Andrade, J. P., 
Martínez, V., Codina, C., Viladomat, F. 2011, Recent Advances in 
Pharmaceutical Science, Muñoz-Torrero, D. (Eds.), Transworld Research 
Network, Kerala, 65. 
3. Chase, M. W., Reveal, J. L., Fay, M. F. 2009, Bot. J. Linn. Soc., 161, 132. 
Laura Torras-Claveria et al. 80 
4. Meerow, A. W., Snijman, D. A. 1998, The Families and Genera of Vascular 
Plants, Kubitzki, K. (Eds.), Springer, Berlin, Vol 3, 83. 
5. Kornienko, A., Evidente, A. 2008, Chem. Rev., 108, 1982. 
6. de Andrade, J. P., Pigni, N. B., Torras-Claveria, L., Berkov, S., Codina, C., 
Viladomat, F., Bastida, J. 2012, J. Pharm. Biomed. Anal., 70, 13. 
7. Torras-Claveria, L., Berkov, S., Codina, C., Viladomat, F., Bastida, J. 2014, Ind. 
Crop. Prod., 56, 211. 
8. Bastida, J., Lavilla, R., Viladomat, F. 2006, The Alkaloids, Cordell, G. A. (Eds.), 
Elsevier, San Diego, 63, 87 
9. Bastida, J., Viladomat, F., Codina, C. 1998, Studies in Natural Products 
Chemistry, Atta-ur-Rahman (Eds.), Elsevier, Amsterdam, 20, 323. 
10. Berkov, S., Martinez-Frances, V., Bastida, J., Codina, C., Rios, S. 2014, 
Phytochemistry, 99, 95. 
11. Pigni, N. B., Berkov, S., Elamrani, A., Benaissa, M., Viladomat, F., Codina, C., 
Bastida, J. 2010, Molecules, 15, 7083. 
12. Pigni, N. B., Ríos-Ruiz, S., Martínez-Francés, V., Nair, J. J., Viladomat, F., 
Codina, C., Bastida, J. 2012, J. Nat. Prod., 75, 1643. 
13. Pigni, N. B., Ríos-Ruiz, S., Luque, F. J., Viladomat, F., Codina, C., Bastida, J. 
2013, Phytochemistry, 95, 384. 
14. Torras-Claveria, L., Berkov, S., Codina, C., Viladomat, F., Bastida, J. 2013, Ind. 
Crop. Prod., 43, 237. 
15. Mander, M., Ntuli, L., Diederichs, N., Mavunla K. 2007, South African Health 
Review, 13, 189.  
16. Nair, J. J., van Staden, J. 2013, Food Chem. Toxicol., 62, 262. 
17. Cheesman, L., Nair, J. J., van Staden, J. 2012, J. Ethnopharmacol., 140, 405. 
18. Viladomat, F., Bastida, J., Codina, C., Nair, J. J., Campbell, W. E. 1997, Recent 
Research Developments in Phytochemistry, Pandalai, S. G. (Eds.), Research 
Signpost Publishers, Trivandrum, 131. 
19. Nair, J. J., Bastida, J., Codina, C., Viladomat, F., van Staden, J. 2013, Nat. Prod. 
Commun., 8, 1335. 
20. Osorio, E. J., Berkov, S., Brun, R., Codina, C., Viladomat, F. 2010, Phytochem. 
Lett., 3, 161. 
21. Reyes-Chilpa, R., Berkov, S., Hernández-Ortega, S., Jankowski C. K., Arseneau, S., 
Clotet-Codina, I., Esté, J. A., Codina, C., Viladomat, F., Bastida, J. 2011., 
Molecules, 16, 9520. 
22. Ortiz, J. E., Berkov, S., Pigni, N. B., Theoduloz, C., Roitman, G., Tapia, A., 
Bastida, J., Ferensin, G. E. 2012, Molecules, 17, 13473. 
23. Cabezas, F., Pigni, N., Bastida, J., Codina, C., Viladomat, F. 2013, Rev. 
Latinoamer. Quím., 41, 68. 
24. Guerrieri, C. G., Pigni, N. B., de Andrade, J. P., dos Santos, V. D., Binns, F., 
Borges, W., Viladomat, F., Bastida, J. 2016. Arab J Chem, 9,688. 
25. de Andrade, J. P., Pigni, N. B., Torras-Claveria, L., Guo, Y., Berkov, S.,             
Reyes-Chilpa, R., El Amrani, A., Zuanazzi, J. A. S., Codina, C., Viladomat, F., 
Bastida, J. 2012, Rev. Latinoamer, Quím., 40, 83. 
New perspectives for ornamental Amaryllidaceae plants 81 
26. Giordani, R. B., de Andrade, J. P., Verli, H., Dutilh, J. H., Henriques, A. T., 
Berkov, S., Bastida, J., Zuanazzi, J. A. 2011, Magn. Reson. Chem., 49, 668. 
27. de Andrade, J. P., Berkov, S., Viladomat, F., Codina, C., Zuanazzi, J. A. S., 
Bastida, J. 2011, Molecules, 16, 7097. 
28. de Andrade, J. P., Guo, Y., Font-Bardia, M., Calvet, T., Dutilh, J., Viladomat, F., 
Codina, C., Nair, J. J., Zuanazzi, J. A. S., Bastida, J. 2014, Phytochemistry,                 
103, 188. 
29. Sebben, C., Giordani, R. B., de Andrade, J. P., Berkov, S., Osorio, E. J., Sobral, M., 
de Almeida, M. V., Henriques, A. T., Bastida, J., Zuanazzi, J. A. S. 2015, Rev. 
Bras. Farmacogn.-Braz. J. Pharmacogn., 25, 353. 
30. Guo, Y., de Andrade, J. P., Pigni, N. B., Torras-Claveria, L., Tallini, L. R., 
Borges, W. S., Viladomat, F., Nair, J. J., Zuanazzi, J. A. S., Bastida, J. 2016, 
Helv. Chim. Acta, 99, 143. 
31. Ortiz, J. E., Pigni, N. B., Andujar, S. A., Roitman, G., Suvire, F. D., Enriz, R. D., 
Tapia, A., Bastida, J., Ferensin, G. E. 2016, J. Nat. Prod., 79, 1241. 
32. Berkov, S., Georgieva, L., Kondakova, V., Viladomat, F., Bastida, J., Atanassov, 
A., Codina, C. 2013, Biochem. Syst. Ecol., 46, 152. 
33. Weniger, B., Italiano, L., Beck, J. P., Bastida, J., Bergoñón, S., Codina, C., 
Lobstein, A., Anton, R. 1995, Planta Med., 61, 77. 
34. Campbell, W. E., Nair, J. J., Gammon, D. W., Bastida, J., Codina, C., 
Viladomat, F., Smith, P. J., Albrecht, C. F. 1998, Planta Med., 64, 91. 
35. Berkov, S., Romani, S., Herrera, M., Viladomat, F., Codina, C., Momekov, G., 
Ionkova, I., Bastida, J. 2011, Phytoter. Res. 25, 1986. 
36. Nair, J. J., Rárová, L., Strnad, M., Bastida, J., van Staden, J. 2012, Bioorg. Med. 
Chem. Lett., 22, 6195. 
37. McNulty, J., Nair, J.J., Codina, C., Bastida, J., Pandey, S., Gerasimoff, J., 
Griffin, C. 2007, Phytochemistry, 68, 1068. 
38. McNulty, J., Nair, J. J., Bastida, J., Pandey, S., Griffin, C. 2009, Nat. Prod. 
Commun. 4, 483. 
39. McNulty, J., Nair, J. J., Bastida, J., Pandey, S., Griffin, C. 2009, Phytochemistry, 
70, 913. 
40. Nair, J. J., Bastida, J., Viladomat, F., van Staden, J. 2012, Nat. Prod. Commun. 
7, 1677. 
41. Osorio, E. J., Robledo, S. M., Bastida, J. 2008, The Alkaloids, Chemistry and 
Biology, Cordell, G. A. (Eds.), Elsevier, San Diego, 66, 113. 
42. Kaya, G. I., Sarikaya, B., Onur, M. A., Somer, N. U., Viladomat, F., Codina, C., 
Bastida, J., Lauinger, I. L., Kaiser, M., Tasdemir, D. 2011, Phytochem. Lett.,             
4, 301. 
43. Maelicke, A., Samochocki, M., Jostock, R., Fehrenbacher, A., Ludwig, J., 
Albuquerque, E. X., Zerlin, M. 2001, Biol. Psychiatry, 49, 2479. 
44. López, S., Bastida, J., Viladomat, F., Codina, C. 2002, Life Sci., 71, 2521. 
45. Pagliosa, L. B., Monteiro, S. C., Silva, K. B., de Andrade, J. P., Dutilh, J., 
Bastida, J., Cammarota, M., Zuanazzi, J. A. S. 2010, Phytomedicine, 17, 698. 
46. de Andrade, J. P., Giordani, R. B., Torras-Claveria, L., Pigni, N. B., Berkov, S., 
Font-Bardia, M., Calvet, T., Konrath, E., Bueno, K., Sachett, L. G., Dutilh, J. H., 
Laura Torras-Claveria et al. 82 
Borges, W. S., Viladomat, F., Henriques, A. T., Nair, J. J., Zuanazzi, J. A. S., 
Bastida, J. 2016, Phytochem. Rev., 15, 147. 
47. Bores G.M.,  Huger, F.P., Petko, W., Mutlib, A.E., Camacho, F., Rush, D.K., 
Selk, D.E., Wolf, V., Kosley, R.W., Davis, L., Vargas, H.M. 1996,                             
J. Pharmacol. Exp. Ther., 277, 728. 
48. Berkov, S., Codina, C., Viladomat, F., Bastida, J. 2008, Bioorg. Med. Chem. 
Lett., 18, 2263. 
49. Meng, X., Zhang, H., Mezei, M., Cui, M. 2011, Curr. Comput. Aided Drug Des., 
7, 146. 
50. Cortes, N., Alvarez, R., Osorio, E. H., Alzate, F., Berkov, S., Osorio, E. 2015,                   
J. Pharm. Biomed. Anal., 102, 222. 
51. García, I., Fall, Y., Gómez, G. 2010, Curr. Pharm. Design, 16, 2666. 
 
 
 
 
 
